The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
905
September 17, 1993
View Complete Issue         Table of Contents 2019 
Tacrine for Alzheimer's Disease
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Tacrine for Alzheimer's Disease
September 17, 1993 (Issue: 905)
Tacrine hydrochloride (Cognex - Parke-Davis), an acridinamine derivative, will soon be available for treatment of cognitive deficits associated with Alzheimer's disease.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Tacrine for Alzheimer's Disease
Article code: 905a
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.